Sionna Therapeutics (NASDAQ:SION) Posts Earnings Results, Misses Estimates By $0.10 EPS

Sionna Therapeutics (NASDAQ:SION) released its quarterly earnings results on Tuesday. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.10), FiscalAI reports.

Here are the key takeaways from Sionna Therapeutics’ conference call:

• The Phase IIa PreciSION study missed the company’s efficacy expectations, disappointing management. A post hoc analysis excluding three patients it considered non-adherent showed a 4-to-9-point sweat-chloride improvement, still below its 10-point target.
• Sionna hypothesizes that combining SION-719 with TRIKAFTA caused “anti-synergy,” including a 25%–30% drop in TRIKAFTA exposure and a possible biological interaction with its potentiator. The company said the small dataset and sparse pharmacokinetic measurements prevent it from confirming or quantifying these explanations.
• Sionna plans to start a Phase II proof-of-concept study in the first quarter, testing a 28-day, open-label switch from TRIKAFTA to its potentiator-free SION-451/SION-2222 combination, with sweat chloride as the primary activity endpoint. The protocol and study size are still being finalized, so the efficacy and enrollment outlook remain uncertain.
• The company reported $250 million in cash at the end of Q3 and runway into the second half of 2029, providing funding for its planned clinical work.

Sionna Therapeutics Stock Performance

SION stock traded down $0.28 during midday trading on Thursday, reaching $3.42. The stock had a trading volume of 20,479 shares, compared to its average volume of 966,950. The firm has a fifty day simple moving average of $5.06 and a two-hundred day simple moving average of $28.64. The stock has a market cap of $154.57 million, a PE ratio of -1.40 and a beta of 1.23. Sionna Therapeutics has a 52-week low of $3.19 and a 52-week high of $54.97.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Lifesci Capital lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Royal Bank Of Canada upgraded shares of Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price target on the stock in a report on Monday, August 10th. Stifel Nicolaus downgraded shares of Sionna Therapeutics from a “buy” rating to a “hold” rating and set a $7.00 price objective on the stock. in a research report on Monday, August 10th. Wall Street Zen lowered shares of Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Raymond James Financial downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $42.33.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Ra Capital Management, L.P. sold 3,448,811 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $6.33, for a total value of $21,830,973.63. Following the completion of the transaction, the director directly owned 3,448,812 shares in the company, valued at $21,830,979.96. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

A number of large investors have recently bought and sold shares of SION. BlackRock Inc. acquired a new stake in shares of Sionna Therapeutics in the second quarter worth $64,875,000. Jennison Associates LLC increased its holdings in Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after buying an additional 335,942 shares in the last quarter. Artia Global Partners LP acquired a new position in shares of Sionna Therapeutics in the second quarter worth about $5,267,000. Walleye Capital LLC acquired a new position in shares of Sionna Therapeutics in the second quarter worth about $4,282,000. Finally, Bank of America Corp DE purchased a new stake in shares of Sionna Therapeutics during the 2nd quarter worth about $3,911,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, a genetic disease caused by defects in the CFTR protein. The company’s research aims to address the underlying protein dysfunction rather than only manage the symptoms of the disease. Its pipeline includes small-molecule candidates designed to stabilize or correct CFTR, with the goal of restoring the protein’s function. Sionna is investigating these candidates as potential components of combination therapies for people with cystic fibrosis.